AbbVie showcases broad blood cancer pipeline at EHA 2026 with 21 presentations
The company will present 21 oral and poster presentations spanning investigational and approved therapies
The company will present 21 oral and poster presentations spanning investigational and approved therapies
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
Subscribe To Our Newsletter & Stay Updated